NCT05792995View on ClinicalTrials.gov

Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2023

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Sindillimab

Any treatment regimen that includes immunotherapy.

Trial Locations (1)

443003

Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang

All Listed Sponsors
lead

Xin-Hua Xu

OTHER

NCT05792995 - Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes | Biotech Hunter | Biotech Hunter